DuPont — Nov 6, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001666700-25-000058
Showing in the filing
Targeted payout ratio
“35-45%”
Period
No period stated
Measure
Company-defined measure
Source
Prose
All guidance in this release · 15
Operating EBITDA for new DuPont for FY2025
“$1.6 billion”
Share repurchase authorization
“up to $2 billion”
Quarterly dividend
“$0.20 per share”
Quarterly dividend for new DuPont
“$0.20 per share”
Targeted payout ratio for the long term
“35%-45%”
Accelerated share repurchase (ASR)
“$500 million”
Targeted payout ratio
“35-45%”
Net sales for FY2025
“~$6,840”
Net sales for Q4 FY2025
“~$1,685”
Operating EBITDA for FY2025
“~$1,600”
Operating EBITDA for Q4 FY2025
“~$385”
Adjusted EPS for FY2025
“~$1.66”
Adjusted EPS for Q4 FY2025
“~$0.43”
Organic sales growth for FY2025
“up 2 percent year-over-year”
Estimated amortization expense in 2025 assoc… for FY2025
“about $290 million on a pre-tax basis, or approximately $0.50 per share”
Exhibit 99.1 · the passage around this item
… earlier in the release
Quarterly Dividend The Company today also announced that its Board of Directors has declared a quarterly dividend for new DuPont of $0.20 per share on its outstanding common stock, payable December 15, 2025, to holders of record at the close of business on November 28, 2025. The dividend is in line with new DuPont’s targeted 35-45% payout ratio. (4) Under the $2B Authorization, repurchases may be made from time to time on the open market at prevailing market prices or in privately negotiated transactions off market. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. 2 Third Quarter 2025 Segment Highlights IndustrialsCo (3) Dollars in millions, unless noted 3Q’25 3Q’24 Change vs. 3Q’24 Organic Sales (2) vs. 3Q’24 Net sales $1,797 $1,715 5% 4% Operating EBITDA $465 $445 4% Operating EBITDA margin % 25.9 % 25.9 % flat Net sales • Net sales increased 5% on organic sales growth of 4% and a currency benefit of 1%. Organic growth includes an approximately $30 million benefit from order timing related to system cut-over activities in advance of the planned electronics separation. ◦ Healthcare & Water Technologies sales up high-single digits on strong organic growth with increases in both businesses. Volume gains were driven by growth for medical packaging and biopharma and continued strength in reverse osmosis and ion exchange. ◦ Diversified Industrials sales up low-single digits on an organi
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.